Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

GSK And Regulus Seal RNA Drug Pact

April 28, 2008 | A version of this story appeared in Volume 86, Issue 17

GlaxoSmithKline has teamed up with Regulus Therapeutics, a joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, to discover and develop microRNA-targeted drugs. Regulus will develop microRNA antagonists against four targets related to inflammatory disease through clinical proof of concept; GSK will then have the option to license those drugs for further development. GSK will pay Regulus $20 million up front plus up to $144.5 million in milestones for each target developed in the deal. MicroRNAs are small single-stranded RNAs that regulate the expression of many human genes.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.